2-Chlorocyclohepta-2,4,6-trienone
| Code | Size | Price |
|---|
| CDX-C0181-G001 | 1 g | £108.00 |
Quantity:
| CDX-C0181-G002 | 2 g | £181.00 |
Quantity:
| CDX-C0181-G010 | 10 g | £574.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4 °C
Documents
Further Information
Alternate Names/Synonyms:
2-Chloro-2,4,6-cycloheptatrien-1-one; 2-Chlorotropone
Appearance:
Light yellow powder with lumps.
CAS:
3839-48-3
Class:
8
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS05,GHS07,GHS08
Handling Advice:
Protect from light and moisture.
Hazards:
H302, H314, H317, H334
InChi:
InChI=1S/C7H5ClO/c8-6-4-2-1-3-5-7(6)9/h1-5H
InChiKey:
MTHNMAUDCHXFMM-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 3839-48-3. Formula: C7H5ClO. MW: 140.57. Synthetic. Building block for synthesis.
MDL:
MFCD00182497
Molecular Formula:
C7H5ClO
Molecular Weight:
140.57
Package Type:
Vial
PG:
III
Precautions:
P261, P280, P305, P351, P338, P310
Product Description:
Building block for synthesis.
Purity:
>98% (GC)
Signal word:
Danger
SMILES:
ClC1=CC=CC=CC1=O
Solubility Chemicals:
Soluble in chloroform.
Source / Host:
Synthetic.
Transportation:
Excepted Quantity
UN Nummer:
UN 3261
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | 2-Bromoacrolein | CDX-B0251 | Chemodex | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N-(3-Bromopropyl)-7-nitro-2,1,3-benzoxadiazol-4-amine | CDX-B0268 | Chemodex | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||